venetoclax
Adaptive Biotechnologies, Genentech Partner on MRD Testing in Venetoclax Clinical Trial
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.